JP7365237B2 - シグマ－２受容体の新規調節物質およびその使用方法 - Google Patents

シグマ－２受容体の新規調節物質およびその使用方法 Download PDF

Info

Publication number
JP7365237B2
JP7365237B2 JP2019551998A JP2019551998A JP7365237B2 JP 7365237 B2 JP7365237 B2 JP 7365237B2 JP 2019551998 A JP2019551998 A JP 2019551998A JP 2019551998 A JP2019551998 A JP 2019551998A JP 7365237 B2 JP7365237 B2 JP 7365237B2
Authority
JP
Japan
Prior art keywords
ethyl
cycloalkyl
linear
alkyl
diazaspiro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019551998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511506A5 (https=
JP2020511506A (ja
Inventor
ベンジャミン イー． ブラス，
ダニエル ジェイ． キャニー，
ケビン エム． ブラットナー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2020511506A publication Critical patent/JP2020511506A/ja
Publication of JP2020511506A5 publication Critical patent/JP2020511506A5/ja
Priority to JP2023174368A priority Critical patent/JP7781122B2/ja
Application granted granted Critical
Publication of JP7365237B2 publication Critical patent/JP7365237B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019551998A 2017-03-21 2018-03-15 シグマ－２受容体の新規調節物質およびその使用方法 Active JP7365237B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023174368A JP7781122B2 (ja) 2017-03-21 2023-10-06 シグマ－２受容体の新規調節物質およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762474277P 2017-03-21 2017-03-21
US62/474,277 2017-03-21
PCT/US2018/022574 WO2018175188A1 (en) 2017-03-21 2018-03-15 Novel modulators of the sigma-2 receptor and their method of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023174368A Division JP7781122B2 (ja) 2017-03-21 2023-10-06 シグマ－２受容体の新規調節物質およびその使用方法

Publications (3)

Publication Number Publication Date
JP2020511506A JP2020511506A (ja) 2020-04-16
JP2020511506A5 JP2020511506A5 (https=) 2021-04-22
JP7365237B2 true JP7365237B2 (ja) 2023-10-19

Family

ID=63585700

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019551998A Active JP7365237B2 (ja) 2017-03-21 2018-03-15 シグマ－２受容体の新規調節物質およびその使用方法
JP2023174368A Active JP7781122B2 (ja) 2017-03-21 2023-10-06 シグマ－２受容体の新規調節物質およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023174368A Active JP7781122B2 (ja) 2017-03-21 2023-10-06 シグマ－２受容体の新規調節物質およびその使用方法

Country Status (5)

Country Link
US (3) US10961249B2 (https=)
EP (1) EP3600290B1 (https=)
JP (2) JP7365237B2 (https=)
MA (1) MA49019A (https=)
WO (1) WO2018175188A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023168623A (ja) * 2017-03-21 2023-11-24 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ－２受容体の新規調節物質およびその使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970223B1 (en) 2013-03-11 2020-04-15 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
US10544117B2 (en) 2014-09-10 2020-01-28 Temple University—Of the Commonwealth System of Higher Education 5-hydroxytryptamine receptor 7 activity modulators and their method of use
AU2017361078B2 (en) 2016-11-15 2022-01-06 Praeventix, Llc Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
MA49017A (fr) * 2017-03-21 2020-02-05 Univ Temple Modulateurs du récepteur 7 de la 5-hydroxytryptamine et utilisation de ces derniers en tant qu'agents thérapeutiques
EA202092328A1 (ru) 2018-05-11 2021-04-08 Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения
GB201809295D0 (en) 2018-06-06 2018-07-25 Institute Of Cancer Res Royal Cancer Hospital Lox inhibitors
CN112010859B (zh) * 2019-05-30 2022-07-19 中国科学院上海药物研究所 一种并环化合物、其制备方法和用途
CN120379996A (zh) * 2022-08-11 2025-07-25 瑞敏德股份有限公司 用于治疗神经退行性障碍的(氮杂)螺庚烷衍生物

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526333A (ja) 2004-03-03 2007-09-13 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
JP2010509402A (ja) 2006-11-13 2010-03-25 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド Ａ１アデノシン受容体のアロステリック調節剤
JP2011519936A (ja) 2008-05-09 2011-07-14 アボット・ラボラトリーズ ニューロンニコチン受容体のための選択的リガンドおよびこれらの使用
US20130178458A1 (en) 2012-01-06 2013-07-11 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine m1 receptors
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2014164756A1 (en) 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016055394A1 (en) 2014-10-08 2016-04-14 F. Hoffmann-La Roche Ag Spirodiamine derivatives as aldosterone synthase inhibitors
WO2016183150A1 (en) 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP2016540792A (ja) 2013-12-20 2016-12-28 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対して多重モードの活性を有するピペラジン誘導体
JP2019535825A (ja) 2016-11-15 2019-12-12 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ ５−ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法
JP2020511515A (ja) 2017-03-21 2020-04-16 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ ５−ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0419192D0 (en) 2004-08-27 2004-09-29 Merck Sharp & Dohme Therapeutic agents
WO2014085413A1 (en) 2012-11-28 2014-06-05 Temple University - Of The Commonwealth System Of Higher Education Disubstituted oxazolidin-2-ones 5-hydroxytryptamine receptor 2b activity modulators
AU2013355054B2 (en) 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
AR103297A1 (es) 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MA49019A (fr) 2017-03-21 2020-02-05 Univ Temple Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
EA202092328A1 (ru) 2018-05-11 2021-04-08 Темпл Юниверсити-Оф Зэ Коммонвелс Систем Оф Хаер Эдьюкейшн Новые функционализированные лактамы в качестве модуляторов 5-гидрокситриптаминового рецептора 7 и способ их применения
JP7730811B2 (ja) 2019-11-13 2025-08-28 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション ５－ヒドロキシトリプタミン受容体７の調節因子としての新規官能化ラクタムおよびその使用方法
WO2021097117A2 (en) 2019-11-13 2021-05-20 Temple University-Of The Commonwealth System Of Higher Education Novel functionalized lactones as modulators of the 5-hydroxytryptamine receptor 7 and their method of use

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526333A (ja) 2004-03-03 2007-09-13 ケモセントリックス インコーポレーティッド 二環式および架橋した窒素複素環
JP2010509402A (ja) 2006-11-13 2010-03-25 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド Ａ１アデノシン受容体のアロステリック調節剤
JP2011519936A (ja) 2008-05-09 2011-07-14 アボット・ラボラトリーズ ニューロンニコチン受容体のための選択的リガンドおよびこれらの使用
US20130178458A1 (en) 2012-01-06 2013-07-11 Vanderbilt University Substituted (1-(methylsulfonyl)azetidin-3-yl)(heterocycloalkyl)methanone analogs as antagonists of muscarinic acetylcholine m1 receptors
WO2014164756A1 (en) 2013-03-11 2014-10-09 Temple University Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2014160592A2 (en) 2013-03-27 2014-10-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
JP2016540792A (ja) 2013-12-20 2016-12-28 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対して多重モードの活性を有するピペラジン誘導体
WO2016040554A1 (en) 2014-09-10 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016055394A1 (en) 2014-10-08 2016-04-14 F. Hoffmann-La Roche Ag Spirodiamine derivatives as aldosterone synthase inhibitors
WO2016183150A1 (en) 2015-05-12 2016-11-17 Temple University-Of The Commonwealth System Of Higher Education Novel sigma-2 receptor binders and their method of use
JP2019535825A (ja) 2016-11-15 2019-12-12 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ ５−ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法
JP2020511515A (ja) 2017-03-21 2020-04-16 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイションＴｅｍｐｌｅ Ｕｎｉｖｅｒｓｉｔｙ−Ｏｆ Ｔｈｅ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｓｙｓｔｅｍ Ｏｆ Ｈｉｇｈｅｒ Ｅｄｕｃａｔｉｏｎ ５−ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bhandare, R. R. et al.，Modifications to five-substituted 3,3-diethyl-4,5-dihydro-2(3H)-furanones en route to novel muscarinic receptor ligands，Med Chem Res，2011年，20，pp. 558-565

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023168623A (ja) * 2017-03-21 2023-11-24 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ－２受容体の新規調節物質およびその使用方法
JP7781122B2 (ja) 2017-03-21 2025-12-05 テンプル・ユニバーシティ－オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション シグマ－２受容体の新規調節物質およびその使用方法

Also Published As

Publication number Publication date
US12577251B2 (en) 2026-03-17
JP2023168623A (ja) 2023-11-24
EP3600290A4 (en) 2020-08-12
WO2018175188A1 (en) 2018-09-27
EP3600290A1 (en) 2020-02-05
MA49019A (fr) 2020-02-05
JP7781122B2 (ja) 2025-12-05
US20200039985A1 (en) 2020-02-06
US20240300954A1 (en) 2024-09-12
JP2020511506A (ja) 2020-04-16
US10961249B2 (en) 2021-03-30
EP3600290C0 (en) 2025-06-04
EP3600290B1 (en) 2025-06-04
US11820774B2 (en) 2023-11-21
US20210363145A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7781122B2 (ja) シグマ－２受容体の新規調節物質およびその使用方法
JP7705909B2 (ja) ５－ヒドロキシトリプタミン受容体７調節物質および治療剤としてのその使用
JP7482948B2 (ja) ５－ヒドロキシトリプタミン受容体７の新規調節因子およびその使用方法
EP3200589B1 (en) Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
CN112437768B (zh) 作为5-羟色胺受体7调节剂的新型官能化内酰胺及其使用方法
EP2970223B1 (en) Novel 5-hydroxytryptamine receptor 7 activity modulators and their method of use
WO2016183150A1 (en) Novel sigma-2 receptor binders and their method of use
KR20260053219A (ko) 5-히드록시트립타민 수용체 7의 신규 조절제 및 이의 사용 방법
HK40014762B (en) 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression
HK40014762A (en) 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxa-8-azaspiro[4.5]decan-1-one derivatives and related compounds as 5-hydroxytryptamine receptor 7 (5-ht7) modulators for treating e.g. inflammatory bowel disease, circadian rhythm disorder or depression

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230310

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231006

R150 Certificate of patent or registration of utility model

Ref document number: 7365237

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150